[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-neoplasm-malignant-stage-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-neoplasm-malignant-stage-i":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100458257",false,"NCT05247268","Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer","Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer","Inclusion Criteria:\n\n* Consent informed and signed\n* Primarily have a confirmed diagnosis of early-stage endometrial cancer (endometrioid, grade I, without myometrial inva- sion) ) based upon endometrial biopsy, diagnostic curettage or hysteroscopy\n* No signs of suspicious myometrial invasion or extrauterine metastasis by enhanced magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal ultrasonography (TVUS)\n* Have a strong desire for remaining reproductive function or uterus\n* Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time\n\nExclusion Criteria:\n\n* Pathologically confirmed as endometrial cancer with suspicious myometrial invasion or extrauterine metastasis\n* Recurrent endometrial cancer\n* Combined with severe medical disease or severely impaired liver and kidney function\n* Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone- dependent tumors that cannot be used with progesterone\n* Those who require hysterectomy or other methods other than conservative treatment with drugs\n* Known or suspected pregnancy\n* Contraindication for Medroxyprogesterone Acetate, Megestrol Acetate, Triprorelin Acetate, Letrozole or pregnancy\n* Hormone treatment within 3 months before entering the trial;\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* Smoker(\\>15 cigarettes a day)",true,"FEMALE","18 Years","45 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA\u002FMPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.",[27],"Endometrial Neoplasm Malignant Stage I",[29,30,31,32],"early endometrial carcinoma","fertility-preserving treatment","gonadotropin-releasing hormone analogue","aromatase inhibitors","RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-04","ACTUAL",{"date":39,"type":37},"2022-03-11",{"date":41,"type":21},"2027-09-10",{"name":43,"class":44},"Fudan University","OTHER",1,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100511896","NCT05945407","Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","Establishment of a Network Platform for Fertility-sparing in Patients With Endometrial Cancer and Study on Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer.","Inclusion Criteria:\n\n* Stage IA (FIGO 2009) ;\n* Pathological diagnosis: endometrial adenocarcinoma G1-G2;\n* MRI or ultrasound: tumor limited to endometrium or invading less than 1\u002F2 of myometrium；\n* 18 years old ≤ Age ≤ 45 years old;\n* With a strong desire for fertility preservation；\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Complicated with any other malignancy；\n* Contraindications to conservative treatment；\n* Contraindications to progestin use;\n* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.",{"count":53,"type":21},57,[55],"NA","The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1\u002F2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.",[58,59,27,60,61],"Endometrial Neoplasms","Endometrial Neoplasm Malignant","Carcinoma, Endometrioid","Fertility Preservation",[63,64,65,66,67],"Fertility-sparing","Fertility-preserving","Endometrial Carcinoma","Endometrial Cancer","Indication Extension","2023-07-12",{"date":70,"type":37},"2023-07-14",{"date":72,"type":37},"2016-08-01",{"date":74,"type":21},"2027-12-31",{"name":76,"class":44},"Peking University People's Hospital",""]